OPM-101
Cancer patients resistant to immune checkpoint inhibitors (e.g., Melanoma)
Key Facts
About Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded biotech focused on developing innovative therapeutic and diagnostic solutions for resistant cancers and neurodegenerative diseases. Its core strength lies in the Nanocyclix® platform, which generates highly selective macrocyclic kinase inhibitors, enabling a pipeline with first-in-class and best-in-class potential. The company has secured strategic validation and funding from The Michael J. Fox Foundation for its Parkinson's program and is advancing multiple clinical-stage assets while exploring radiotheranostic approaches through collaborative projects like COMETE.
View full company profileAbout Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded biotech focused on developing innovative therapeutic and diagnostic solutions for resistant cancers and neurodegenerative diseases. Its core strength lies in the Nanocyclix® platform, which generates highly selective macrocyclic kinase inhibitors, enabling a pipeline with first-in-class and best-in-class potential. The company has secured strategic validation and funding from The Michael J. Fox Foundation for its Parkinson's program and is advancing multiple clinical-stage assets while exploring radiotheranostic approaches through collaborative projects like COMETE.
View full company profile